← 返回

通过锌指蛋白重编程肿瘤免疫:肿瘤免疫治疗的新前沿

英文原题:Rewiring tumor immunity via zinc finger proteins: a new frontier in cancer immunotherapy.

查看英文原题

Rewiring tumor immunity via zinc finger proteins: a new frontier in cancer immunotherapy.

PubMed 2025/12/11(内容时间) J Transl Med Q1 · IF 9.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

作为肿瘤免疫调节网络中的关键节点,靶向 ZFP 的策略为克服当前治疗瓶颈提供了新的机会。

研究思路结论见上方概要

锌指蛋白(ZFPs)是人类基因组中最大且结构最多样化的转录因子家族。它们通过特征性的锌指结构域发挥作用,能够特异性结合 DNA、RNA 和蛋白质,在肿瘤免疫微环境中发挥核心调控作用。正文:本综述系统探讨了 ZFPs 在动态调控癌症先天性和适应性免疫应答中的双重功能。在先天免疫层面,ZFPs 精确控制树突状细胞(DC)的命运决定,决定巨噬细胞极化,平衡自然杀伤(NK)细胞活化,介导髓源性抑制细胞(MDSC)的免疫抑制功能,并调节先天免疫传感器和炎症小体。在适应性免疫中,ZFPs 对 T 细胞效应功能具有关键影响,并调控 B 细胞分化。在此基础上,多种靶向 ZFPs 的免疫治疗策略正在涌现。这些策略包括基因编辑、小分子和蛋白水解靶向嵌合体(PROTACs)、与免疫检查点阻断的协同联合,以及 ZFP 工程化的CAR-T(CAR-T)细胞。

展开英文摘要原文

Zinc finger proteins (ZFPs) represent the largest and most structurally diverse family of transcription factors in the human genome. They function through characteristic zinc finger domains that enable specific binding to DNA, RNA, and proteins, playing a central regulatory role in the tumor immune microenvironment. MAIN BODY: This review systematically examines the dual functions of ZFPs in dynamically regulating both innate and adaptive immune responses in cancer. At the innate immunity level, ZFPs precisely control dendritic cell (DC) fate determination, dictate macrophage polarization, balance natural killer (NK) cell activation, mediate myeloid-derived suppressor cell (MDSC) immunosuppressive function, and modulate innate immune sensors and inflammasomes. Within adaptive immunity, ZFPs critically influence T cell effector function and regulate B cell differentiation. Building on these, diverse immunotherapeutic strategies targeting ZFPs are now emerging. These include gene-editing, small molecules and proteolysis-targeting chimeras (PROTACs), synergistic combinations with immune checkpoint blockade, and ZFP-engineered chimeric antigen receptor T (CAR-T) cells.

As pivotal nodes within the tumor immune regulatory network, ZFP-targeting strategies offer novel opportunities to overcome current therapeutic bottlenecks.

论文信息

作者
Zhou Z、Wu L、Luo JL、Li Z、Zhong S
第一作者单位
The Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan Province, China.China
通讯作者单位
The Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan Province, China. swzhong@usc.edu.cn.China
文献类型
综述 · 非美国政府资助研究
期刊
Journal of translational medicine2025 Dec 11
原文标识
PubMed 41382203 · DOI 10.1186/s12967-025-07549-1